BioSpace News Archive

Excelera®, the company behind the Excelera Network, today announced the appointment of Meredith Holt as National Vice President of Sales.

Quotient Limited re-capped recently disclosed milestone achievements which included the completion of a third party feasibility study of its innovative Molecular Disease Screening microarray, the FDA’s acceptance of its 510 submission for both the initial Serological Disease Screening microarray and the MosaiQ™ system and the commencement of European Union field trial activities for the expanded Immunohematology microarray.

Inovio Pharmaceuticals, Inc. announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of INO-4800, Inovio’s vaccine against the recently emerged strain of coronavirus that has killed numerous people and infected thousands more in China to date.

Best Medical International and Best Particle Therapy of TeamBest Companies, have recently entered into a Memorandum of Understanding with the University of Wisconsin Medical Radiation Research Center.

Samsung Ventures has invested in the Danish company INFUSER. The cleantech company offers a unique technology that can revolutionize air purification

Study met the primary endpoint of at least 75% improvement of skin inflammation and key secondary endpoints

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), announces that it will report its financial results for the fiscal 2020 third quarter before financial markets open on February 13, 2020.

Revenue in the fourth quarter of 2019 grew 8 percent, driven by 10 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, contributed 14 percentage points of revenue growth and represented approximately 46 percent of total revenue. Full-year 2019 revenue increased 4 percent to $22.319 billion.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.